Recent Finacing
Recent Raise
Spur is a clinical-stage gene therapy company optimizing transgenes, capsids, dosing and delivery, advancing FLT201 for Gaucher, SBT101 for AMN, a GBA1-targeted Parkinson program, and cardioprotective heart-failure research.
